ReviewFrontiers in cellular and infection microbiology2024
Treatment of infections caused by carbapenem-resistant
Review in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Green-Synthesized Silver Nanoparticles Against Acinetobacter baumannii: A Systematic Review of Antibacterial Activity, Mechanisms of Action, Toxicity, and Antibiofilm Effects.MicrobiologyOpen · 2026Pooled it
- Therapeutic efficacy and mechanisms of Xuebijing inFrontiers in pharmacology · 2025Pooled it
- Predictors of In-Hospital Mortality Among Hospitalized Colistin-Treated Patients at a Tertiary Urology-Nephrology Referral Center.Antibiotics (Basel, Switzerland) · 2026Article
- Repurposing bleomycin against Acinetobacter baumannii HisG: computational, biophysical, and antibacterial evidence.Journal of computer-aided molecular design · 2026Article
- Analysis of clinical characteristics and whole-genome sequencing of carbapenem-resistant Acinetobacter baumannii isolates from pediatric patients in Guangxi, China.BMC microbiology · 2026Article
- Sulbactam-Durlobactam in the Treatment of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Review
- A non-antibiotic genetic selection system enables near-infrared in vivo imaging and evaluation of antibiotic efficacy for multidrug-resistant Acinetobacter baumannii.The Journal of antibiotics · 2026Article
- Design of a multimodal synthetic peptide antibiotic derived from human cathelicidin.Cell biomaterials · 2026Article
- Precision Approaches to Carbapenem-Resistant Infections in the ICU: Integrating Diagnostics, Stewardship, and Novel Therapies.Diagnostics (Basel, Switzerland) · 2026Review
- Capsular polysaccharides of Acinetobacter baumannii modulate antimicrobial resistance and innate immune response.Scientific reports · 2026Article
- High magnitude of carbapenemase-producing Acinetobacter baumannii in sepsis patients at Ethiopian referral hospitals: a whole genome analysis.Scientific reports · 2026Article
- Sulbactam-Durlobactam in the Treatment of Bloodstream Infection Due to Carbapenem-ResistantJournal of clinical medicine · 2026Review
- Characterization of outer membrane vesicles from Acinetobacter haemolyticus and their role in the dissemination of carbapenem resistance.Medical microbiology and immunology · 2026Article
- Prevalence of Carbapenem-Resistant Gram-Negative Bacilli from Intensive Care Units from Latin America and the Caribbean: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2026Review
- Ward microclimate and procedural factors as predictors for CRAB environmental contamination in ICUs: a longitudinal monitoring study.Antimicrobial resistance and infection control · 2026Article
- "Antimicrobial susceptibility of carbapenem-resistant Acinetobacter baumannii against tetracycline, doxycycline, tigecycline, minocycline and colistin: experience from a tertiary care hospital in Karachi".BMC microbiology · 2026Article
- Carbapenem-resistant Acinetobacter baumannii bloodstream infections and specific phages isolation, analysis and application.Frontiers in cellular and infection microbiology · 2026Article
- Impact of multisite colonization and comparative microbiological outcomes of colistin-sulbactam vs. colistin-tigecycline in CRAB hospital-acquired pneumonia: a propensity score-matched analysis.Frontiers in cellular and infection microbiology · 2026Article
- Real-World Clinical Outcomes of Sulbactam-Durlobactam Against Carbapenem-ResistantInfection and drug resistance · 2026Article
- Clonal patient-to-patient spread is associated with multidrug-resistantFrontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with severe carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.